Analyst firms · Raymond James · PTCT
Raymond James PTCT price target and rating history
PTC Therapeutics Inc. (PTCT) · Health Care
Raymond James rates PTC Therapeutics Inc. (PTCT) Outperform with a $108 price target, as of its latest action on Apr 10, 2026. It has published 5 rating actions on PTCT since October 2021, including 1 upgrade and 1 downgrade. Across 8 firms with a PTCT price target in the last 12 months, the median target is $94.50. Raymond James's $108 is 14% above that.
- Current rating
- Outperform
- Price target
- $108
- Median target, all firms
- $94.50
- Actions on PTCT
- 5
Raymond James price target on PTCT
Every Raymond James rating on PTCT
- Apr 10, 2026
- Oct 10, 2024
- May 20, 2024
- Sep 15, 2023
- Oct 29, 2021
How other firms rate PTCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Hold | $62 | Oct 16, 2026 |
| Leerink Partners | Outperform | $98 | Sep 14, 2026 |
| Citigroup | Buy | $108 | Jun 9, 2026 |
| Jefferies | Buy | $85 | May 27, 2026 |
| TD Cowen | Buy | $90 | May 8, 2026 |
| Raymond James | Outperform | $108 | Apr 10, 2026 |
| Barclays | Overweight | $119 | Jan 28, 2026 |
| RBC Capital Markets | Sector Perform | $91 | Dec 1, 2025 |
Questions about Raymond James and PTCT
- What is Raymond James's price target for PTCT?
- Raymond James's latest stated price target for PTC Therapeutics Inc. (PTCT) is $108, from its action on Apr 10, 2026.
- What is Raymond James's rating on PTCT?
- Raymond James rates PTCT Outperform, a bullish rating, as of Apr 10, 2026.
- When did Raymond James last change its view on PTCT?
- On Apr 10, 2026, Raymond James starts coverage at Outperform, price target $108.
- How does Raymond James's PTCT target compare with other analysts?
- Across 8 firms with a PTCT price target in the last 12 months, the median target is $94.50. Raymond James's $108 is 14% above that.
More PTCT rating histories
All Raymond James ratingsPTCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.